Columbia Comprehensive Cancer Panel

Overview

The Columbia Comprehensive Cancer Panel (CCCP) is a targeted DNA sequencing panel covering 467 cancer-associated genes on a 5.59 Mb Custom Agilent SureSelectXT capture library. It was developed at Columbia University Medical Center specifically optimized for formalin-fixed paraffin-embedded (FFPE) material and is run on a CLIA-certified platform, achieving >500-fold average coverage with >98% of coding sequence at ≥10×. It serves as a backup assay when tumor tissue quality is insufficient for whole-exome sequencing.

Used by

• Applied as a FFPE-optimized backup targeted panel (13 of 120 samples) in the PIPseq pediatric precision oncology program at Columbia University Medical Center, alongside cancer whole-exome sequencing and RNA-seq for high-risk pediatric hematology-oncology patients PMID:28007021.

Notes

• 467 cancer-associated genes; 5.59 Mb custom Agilent SureSelectXT library.
• Optimized for FFPE material; achieves >500-fold average coverage.
• CLIA-certified assay at Columbia University Medical Center.
• Used when standard WES is not feasible (e.g., insufficient tissue quality or quantity).

Sources

This page was processed by entity-page-writer on 2026-05-15.